This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia: A Population-Based Nested Case-Control Study

Lone Baandrup, MD; Christiane Gasse, RPharm, PhD;      Vibeke D. Jensen, RPharm; Birte Y. Glenthoj, MD, DMSc;      Merete Nordentoft, MD, PhD, DMSc; Henrik Lublin, MD, DMSc;      Anders Fink-Jensen, MD, DMSc; Anne Lindhardt, MD;      and Preben B. Mortensen, MD, DMSc

Published: November 3, 2009

Article Abstract

Objective: Concomitant prescription of more than 1 antipsychotic agent (antipsychotic polypharmacy) in the treatment of schizophrenia is prevalent, although monotherapy is generally
recommended. Mortality from natural causes
is markedly increased in schizophrenia, and
the role of polypharmacy remains controversial. The objective was to investigate if antipsychotic polypharmacy is associated with the excess mortality from natural causes among patients with schizophrenia.

Method: A population-based nested
case-control study was conducted using patient data from January 1, 1996, to December 31, 2005,
obtained from central Danish registers. From the study population of 27,633 patients with ICD-8– and ICD-10-diagnosed schizophrenia or other mainly nonaffective psychoses, aged 18-53 years, we identified 193 cases who died of natural causes within a 2-year period and 1,937 age- and sex-matched controls. Current drug use was defined
as at least 1 prescription filled within 90 days before the date of death or the index date. The data were analyzed by conditional logistic regression.

Results: Risk of natural death did not increase with the number of concurrently used antipsychotic agents compared with antipsychotic monotherapy (no antipsychotics: adjusted
odds ratio [OR]‘ ‰=‘ ‰1.48 [95% CI, 0.89-2.46]; 2 antipsychotics: OR‘ ‰=‘ ‰0.91 [95% CI, 0.61-1.36]; 3 or more antipsychotics: OR‘ ‰=‘ ‰1.16 [95% CI, 0.68-2.00]). Current use of benzodiazepine derivatives with long elimination half-lives (more than 24 hours) was associated with increased risk of natural death in patients with schizophrenia treated with antipsychotics (OR‘ ‰=‘ ‰1.78 [95% CI, 1.25-2.52]).

Conclusions: Antipsychotic polypharmacy did not contribute to the excess mortality from natural causes in middle-aged patients with schizophrenia. The detected increased risk of death associated with benzodiazepines with long elimination half-lives calls for further clarification.

Submitted: October 23, 2008; accepted January 2, 2009.

Online ahead of print: November 3, 2009.

Corresponding author: Lone Baandrup, MD, Centre for Neuropsychiatric Schizophrenia Research, Psychiatric Centre Glostrup, Copenhagen University Hospital, Glostrup, Nordre Ringvej 29-67, DK-2600 Glostrup, Denmark (

Volume: 70

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF